NATCOPHARM Natco Pharma Ltd Q4'25 & FY25 Results (YoY) Good set of numbers 👍 🚨 Management estimates a possible dip in revenue by 20% & profits by 30% due to geopolitical uncertainties & pricing pressure in its core product portfolio in the US and increased R&D expenses Q4'25 ▶️ Revenue: ₹ 1,221 Cr (+14%) ▶️ EBITDA: ₹ 548 Cr (+10%) ▶️ EBITDA Margin: 44.8% vs 46.5% ▶️ PAT: ₹ 406 Cr (+5%) ▶️ PAT Margin: 33.2% vs 36.1% FY25 ▶️ Revenue: ₹ 4,430 Cr (+11%) ▶️ EBITDA: ₹ 2,196 Cr (+25%) ▶️ EBITDA Margin: 49.5% vs 43.8% ▶️ PAT: ₹ 1,883 Cr (+36%) ▶️ PAT Margin: 42.5% vs 34.7%